Spotlight on Allergy & Immunology

Credits: 0.25 CME / MOC
Influenza: Reducing Complications in High-Risk Patients Through Advanced Treatment Options – Curbside Consult: An Adult Patient With Asthma and Symptoms of Flu
Paul G. Auwaerter, MD, MBA, FIDSA
Vindico

Influenza: Reducing Complications in High-Risk Patients Through Advanced Treatment Options – Curbside Consult: An Adult Patient With Asthma and Symptoms of Flu

Start

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)
/ABIM MOC
Released: June 29, 2020
Expires: June 28, 2021
0.25 hours to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is allergists, immunologists, family practice physicians, general practice physicians, internists, pulmonologists, nurse practitioners, physician assistants, and other health care professionals involved in the management of patients with influenza.

Learning Objectives

Upon successful completion of the activity, participants should be better able to: 

  • Incorporate revised guidelines into practice to improve earlier detection and treatment of patients with influenza and comorbid respiratory conditions.
  • Compare influenza antiviral treatments in terms of their efficacy, safety, and ability to reduce viral shedding and infection in others.
  • Incorporate the most appropriate therapeutic regimen in patients with influenza who are at high risk for complications.

Activity Description

In this educational program, expert faculty will discuss strategies for incorporating the latest information regarding the diagnosis and treatment of influenza into practice. Using challenging case-based examples, faculty will provide guidance on selecting the most appropriate therapeutic regimen to reduce morbidity and mortality in patients with influenza who are at high risk for complications.

Faculty

Activity Chair:
Paul G. Auwaerter, MD, MBA, FIDSA
Sherrilyn and Ken Fisher Professor of Medicine
Clinical Director, Division of Infectious Diseases
Director, Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, MD
  • Disclosure:
  • Consulting Fee: Advanced Biotherapeutics, DiaSorin
  • Ownership Interest: Johnson & Johnson


Faculty:
John J. Russell, MD
Clinical Professor of Family and Community Medicine
Thomas Jefferson University
Sidney Kimmel School of Medicine
Philadelphia, PA
Chair, Department of Family Medicine
Program Director, Family Medicine Residency
Abington – Jefferson Health
Abington, PA
  • Disclosure:
  • Consulting Fee: GlaxoSmithKline, Sanofi Pasteur
  • Speakers Bureau: Sanofi Pasteur


Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Agenda

Curbside Consult: An Adult Patient With Asthma and Symptoms of Flu
Paul G. Auwaerter, MD, MBA, FIDSA and John J. Russell, MD

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.

Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by Accreditation Council for Continuing Medical Education.

Physician assistants participating in the enduring activity can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Physician Assistants (AAPA). AAPA will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non‒FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447.Telephone: 856-994-9400;Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)
/ABIM MOC
Released: June 29, 2020
Expires: June 28, 2021
0.25 hours to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is allergists, immunologists, family practice physicians, general practice physicians, internists, pulmonologists, nurse practitioners, physician assistants, and other health care professionals involved in the management of patients with influenza.

Learning Objectives

Upon successful completion of the activity, participants should be better able to: 

  • Incorporate revised guidelines into practice to improve earlier detection and treatment of patients with influenza and comorbid respiratory conditions.
  • Compare influenza antiviral treatments in terms of their efficacy, safety, and ability to reduce viral shedding and infection in others.
  • Incorporate the most appropriate therapeutic regimen in patients with influenza who are at high risk for complications.

Activity Description

In this educational program, expert faculty will discuss strategies for incorporating the latest information regarding the diagnosis and treatment of influenza into practice. Using challenging case-based examples, faculty will provide guidance on selecting the most appropriate therapeutic regimen to reduce morbidity and mortality in patients with influenza who are at high risk for complications.

Faculty

Activity Chair:
Paul G. Auwaerter, MD, MBA, FIDSA
Sherrilyn and Ken Fisher Professor of Medicine
Clinical Director, Division of Infectious Diseases
Director, Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, MD
  • Disclosure:
  • Consulting Fee: Advanced Biotherapeutics, DiaSorin
  • Ownership Interest: Johnson & Johnson


Faculty:
John J. Russell, MD
Clinical Professor of Family and Community Medicine
Thomas Jefferson University
Sidney Kimmel School of Medicine
Philadelphia, PA
Chair, Department of Family Medicine
Program Director, Family Medicine Residency
Abington – Jefferson Health
Abington, PA
  • Disclosure:
  • Consulting Fee: GlaxoSmithKline, Sanofi Pasteur
  • Speakers Bureau: Sanofi Pasteur


Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Agenda

Curbside Consult: An Adult Patient With Asthma and Symptoms of Flu
Paul G. Auwaerter, MD, MBA, FIDSA and John J. Russell, MD

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.

Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by Accreditation Council for Continuing Medical Education.

Physician assistants participating in the enduring activity can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Physician Assistants (AAPA). AAPA will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non‒FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447.Telephone: 856-994-9400;Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Allergy & Immunology Presentations

0.50 CME / CNE
Postgraduate Institute for Medicine
Case in Point™ Case Challenges in HIV Medicine: Benefits, Barriers, & Best Practices in an Advancing Field - Rapid ART Protocols As a New Standard of Care in HIV

Case in Point™ Case Challenges in HIV Medicine: Benefits, Barriers, & Best Practices in an Advancing Field - Rapid ART Protocols As a New Standard of Care in HIV

Start

Activity Details

Free CME/CNE
0.5 AMA PRA Category 1 Credit(s)
0.5 Contact Hour(s)
Released: January 8, 2021
Expires: January 8, 2022
30 minutes to complete

Statement of Commercial Support

Supported by an independent educational grant from Gilead Sciences, Inc.

Provided By

This activity is jointly provided by Postgraduate Institute for Medicine and Integritas Communications.

Target Audience

This activity is designed to educate HIV specialists and infectious disease clinicians who are involved in the management of patients living with HIV.

Learning Objectives

Upon completion of this activity, the participant should be better able to:

  • Describe the benefits of rapid antiretroviral therapy (ART) and tactics to overcome clinician and system barriers to implementation

Program Description

Since the rapid initiation of antiretroviral therapy (ART) has become more widely available, identified barriers to more widespread adoption of this approach to HIV management—whether faced by patient, provider, or health care system—now need solutions. In this case-based portion of a previous symposium, Dr. Richard Elion, along with Drs. Eric Daar, Seble Kassaye, and Leandro Mena, will elucidate appropriate treatment approaches that integrate established, streamlined models of care and demonstrate optimal implementation of rapid ART. Faculty will guide learners on the important role of patient navigators or linkage to care coordinators in assisting patients to successfully enroll at the clinic, navigate public or private health insurance or drug assistance programs to gain access to ART, and get referrals for needed support services, including counseling or housing assistance.

Within the context of these interactive cases, faculty will share relevant guideline recommendations, newly published data, and their clinical expertise.

Course Chair

Richard A. Elion, MD
Associate Clinical Professor
Department of Clinical Investigations
Whitman-Walker Health
The George Washington University
Washington, District of Columbia

Dr. Richard Elion is a clinical professor of medicine at George Washington University, as well as Research Director, HIV and HCV Research, at the Washington Health Institute, both in Washington, DC. He is the past Director of Clinical Research at Whitman-Walker Health in Washington, DC, where he focused on cutting-edge research in HIV. His tenure at Whitman-Walker Health coincided with the organization being selected in 2013 as part of the AIDS Clinical Trials Group by the National Institutes of Health. Prior to his tenure with Whitman-Walker Health, he served as Co-Director of HIV Services at Washington Free Clinic in Washington, DC, and in various research and clinical capacities in New York and Washington, DC. In addition to being an accomplished educator and clinician, Dr. Elion also develops educational programs around the United States.

Dr. Elion received his medical degree from Temple University in Philadelphia, Pennsylvania, and completed his internship and residency at Duke University in Durham, North Carolina. He also holds a master’s degree in counseling and spiritual psychology from the University of Santa Monica in Santa Monica, California.

Faculty

Eric S. Daar, MD
Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Chief, HIV Services
Lundquist Institute for Biomedical Innovation
Professor of Medicine, David Geffen School of Medicine
University of California, Los Angeles
Torrance, California

Dr. Eric Daar is Interim Chair of the Department of Medicine and Chief of the Division of HIV Medicine at the Harbor-UCLA Medical Center in Torrance, California. He is also a professor of medicine at the David Geffen School of Medicine at UCLA in Los Angeles, California, as well as an investigator for the Lundquist Institute. He earned his medical degree from Georgetown University School of Medicine in Washington, DC, and completed his internship, residency, and fellowship at Cedars-Sinai Medical Center in Los Angeles. His clinical and research interests include a vast range of HIV-related issues that include pathogenesis and treatment of acute and chronic HIV infection, HIV/HCV coinfection, complications of HIV, and novel strategies for assessing and enhancing adherence to therapy. He has authored numerous articles that have been published in peer-reviewed journals and textbooks.

Seble G. Kassaye, MD, MS
Associate Professor of Medicine
Department of Medicine
Division of Infectious Diseases
Georgetown University
Washington, District of Columbia

Dr. Seble Kassaye earned her medical degree from the University of Chicago Pritzker School of Medicine in Illinois before completing her residency training in internal medicine and pediatrics at Mount Sinai Medical Center in New York and her infectious disease fellowship at Stanford University Hospital in California. She also completed a master’s degree in epidemiology at Stanford University. Dr. Kassaye joined the faculty at Georgetown University in December 2012.

Dr. Kassaye’s investigative focus is on clinical and translational research related to HIV with the objective of increasing access to and uptake of effective HIV treatment and prevention modalities by the most at-risk and indigent populations. As the principal investigator of the DC MACS/WIHS Combined Cohort Study, she aims to understand how HIV contributes to comorbidities, metabolic and cardiovascular complications, and long-term treatment outcomes, along with social, psychological, and cognitive effects of HIV. Dr. Kassaye has been a practicing physician in Washington, DC, for almost a decade, including at a tertiary care academic center as well as a community-based clinic in the ward with highest HIV prevalence in southeast DC. Most of her US-based research projects are driven by questions that she identifies in the context of providing care to a highly indigent and socially vulnerable population.

Leandro A. Mena, MD, MPH
Chair and Professor of Population Health Science
Professor of Medicine, Division of Infectious Diseases
Director, Center for HIV/AIDS Research, Education and Policy
The University of Mississippi Medical Center
Jackson, Mississippi

Dr. Leandro Mena is a clinician-researcher and public health advocate with expertise in the prevention and clinical management of sexually transmitted diseases (STDs) and HIV. He is founding chair of the Department of Population Health Science at the University of Mississippi Medical Center, John D. Bower School of Population Health, and professor of medicine in the Division of Infectious Diseases. He directs the Center for HIV/AIDS Research, Education and Policy at the Myrlie Evers-Williams Institute for Elimination of Health Disparities, and serves as the STD Medical Director for the state of Mississippi. He is also the Medical Director of the Five Points Clinic (Jackson’s public STD clinic) and cofounded Open Arms Healthcare Center (first LGBT clinic in Mississippi).

In recognition of his work developing a model program of culturally competent HIV prevention and care for Black men who have sex with men, which is being replicated in other clinics of the country, he was awarded the 2016 Achievement Award by the Gay and Lesbian Medical Association (GLMA). Board certified in infectious diseases, Dr. Mena is a research fellow with the Rural Center for STD/HIV Prevention (Indiana University). His interests include understanding the dynamics of HIV transmission in racial/ethnic, gender, and sexual minorities as well as the development and provision of culturally competent quality health services to these populations.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Integritas Communications. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in this activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour(s).

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COIs are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Richard A. Elion, MD
Grants/Research support: Gilead Sciences, Inc., ViiV Healthcare
Honoraria: Gilead Sciences, Inc., ViiV Healthcare
Speakers Bureau: Gilead Sciences, Inc.

Eric S. Daar, MD
Consulting Fees: Genentech Inc., Gilead Sciences, Inc., Merck Co., Inc.
Contracted Research: Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare

Seble G. Kassaye, MD, MS
Nothing to disclose

Leandro A. Mena, MD, MPH
Consulting Fees: Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare
Contracted Research: Gilead Sciences, Inc., GlaxoSmithKline, Johnson & Johnson, Merck & Co., Inc., Roche, TaiMed Biologics, ViiV Healthcare

The PIM planners and managers have nothing to disclose. The Integritas Communications planners and managers have nothing to disclose.

Instructions to Receive Credit

There are no fees for participating and receiving CE credit for this activity. Participants must read the learning objectives and faculty disclosures and participate in the educational activity. 

A statement of credit will be issued upon receipt of a completed posttest (with a score of 70% or higher) and an activity evaluation form at the conclusion of the activity.

If you have questions regarding the receipt of your certificate, please contact PIM via email at inquiries@pimed.com.

Media

Internet

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Activity Details

Free CME/CNE
0.5 AMA PRA Category 1 Credit(s)
0.5 Contact Hour(s)
Released: January 8, 2021
Expires: January 8, 2022
30 minutes to complete

Statement of Commercial Support

Supported by an independent educational grant from Gilead Sciences, Inc.

Provided By

This activity is jointly provided by Postgraduate Institute for Medicine and Integritas Communications.

Target Audience

This activity is designed to educate HIV specialists and infectious disease clinicians who are involved in the management of patients living with HIV.

Learning Objectives

Upon completion of this activity, the participant should be better able to:

  • Describe the benefits of rapid antiretroviral therapy (ART) and tactics to overcome clinician and system barriers to implementation

Program Description

Since the rapid initiation of antiretroviral therapy (ART) has become more widely available, identified barriers to more widespread adoption of this approach to HIV management—whether faced by patient, provider, or health care system—now need solutions. In this case-based portion of a previous symposium, Dr. Richard Elion, along with Drs. Eric Daar, Seble Kassaye, and Leandro Mena, will elucidate appropriate treatment approaches that integrate established, streamlined models of care and demonstrate optimal implementation of rapid ART. Faculty will guide learners on the important role of patient navigators or linkage to care coordinators in assisting patients to successfully enroll at the clinic, navigate public or private health insurance or drug assistance programs to gain access to ART, and get referrals for needed support services, including counseling or housing assistance.

Within the context of these interactive cases, faculty will share relevant guideline recommendations, newly published data, and their clinical expertise.

Course Chair

Richard A. Elion, MD
Associate Clinical Professor
Department of Clinical Investigations
Whitman-Walker Health
The George Washington University
Washington, District of Columbia

Dr. Richard Elion is a clinical professor of medicine at George Washington University, as well as Research Director, HIV and HCV Research, at the Washington Health Institute, both in Washington, DC. He is the past Director of Clinical Research at Whitman-Walker Health in Washington, DC, where he focused on cutting-edge research in HIV. His tenure at Whitman-Walker Health coincided with the organization being selected in 2013 as part of the AIDS Clinical Trials Group by the National Institutes of Health. Prior to his tenure with Whitman-Walker Health, he served as Co-Director of HIV Services at Washington Free Clinic in Washington, DC, and in various research and clinical capacities in New York and Washington, DC. In addition to being an accomplished educator and clinician, Dr. Elion also develops educational programs around the United States.

Dr. Elion received his medical degree from Temple University in Philadelphia, Pennsylvania, and completed his internship and residency at Duke University in Durham, North Carolina. He also holds a master’s degree in counseling and spiritual psychology from the University of Santa Monica in Santa Monica, California.

Faculty

Eric S. Daar, MD
Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Chief, HIV Services
Lundquist Institute for Biomedical Innovation
Professor of Medicine, David Geffen School of Medicine
University of California, Los Angeles
Torrance, California

Dr. Eric Daar is Interim Chair of the Department of Medicine and Chief of the Division of HIV Medicine at the Harbor-UCLA Medical Center in Torrance, California. He is also a professor of medicine at the David Geffen School of Medicine at UCLA in Los Angeles, California, as well as an investigator for the Lundquist Institute. He earned his medical degree from Georgetown University School of Medicine in Washington, DC, and completed his internship, residency, and fellowship at Cedars-Sinai Medical Center in Los Angeles. His clinical and research interests include a vast range of HIV-related issues that include pathogenesis and treatment of acute and chronic HIV infection, HIV/HCV coinfection, complications of HIV, and novel strategies for assessing and enhancing adherence to therapy. He has authored numerous articles that have been published in peer-reviewed journals and textbooks.

Seble G. Kassaye, MD, MS
Associate Professor of Medicine
Department of Medicine
Division of Infectious Diseases
Georgetown University
Washington, District of Columbia

Dr. Seble Kassaye earned her medical degree from the University of Chicago Pritzker School of Medicine in Illinois before completing her residency training in internal medicine and pediatrics at Mount Sinai Medical Center in New York and her infectious disease fellowship at Stanford University Hospital in California. She also completed a master’s degree in epidemiology at Stanford University. Dr. Kassaye joined the faculty at Georgetown University in December 2012.

Dr. Kassaye’s investigative focus is on clinical and translational research related to HIV with the objective of increasing access to and uptake of effective HIV treatment and prevention modalities by the most at-risk and indigent populations. As the principal investigator of the DC MACS/WIHS Combined Cohort Study, she aims to understand how HIV contributes to comorbidities, metabolic and cardiovascular complications, and long-term treatment outcomes, along with social, psychological, and cognitive effects of HIV. Dr. Kassaye has been a practicing physician in Washington, DC, for almost a decade, including at a tertiary care academic center as well as a community-based clinic in the ward with highest HIV prevalence in southeast DC. Most of her US-based research projects are driven by questions that she identifies in the context of providing care to a highly indigent and socially vulnerable population.

Leandro A. Mena, MD, MPH
Chair and Professor of Population Health Science
Professor of Medicine, Division of Infectious Diseases
Director, Center for HIV/AIDS Research, Education and Policy
The University of Mississippi Medical Center
Jackson, Mississippi

Dr. Leandro Mena is a clinician-researcher and public health advocate with expertise in the prevention and clinical management of sexually transmitted diseases (STDs) and HIV. He is founding chair of the Department of Population Health Science at the University of Mississippi Medical Center, John D. Bower School of Population Health, and professor of medicine in the Division of Infectious Diseases. He directs the Center for HIV/AIDS Research, Education and Policy at the Myrlie Evers-Williams Institute for Elimination of Health Disparities, and serves as the STD Medical Director for the state of Mississippi. He is also the Medical Director of the Five Points Clinic (Jackson’s public STD clinic) and cofounded Open Arms Healthcare Center (first LGBT clinic in Mississippi).

In recognition of his work developing a model program of culturally competent HIV prevention and care for Black men who have sex with men, which is being replicated in other clinics of the country, he was awarded the 2016 Achievement Award by the Gay and Lesbian Medical Association (GLMA). Board certified in infectious diseases, Dr. Mena is a research fellow with the Rural Center for STD/HIV Prevention (Indiana University). His interests include understanding the dynamics of HIV transmission in racial/ethnic, gender, and sexual minorities as well as the development and provision of culturally competent quality health services to these populations.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Integritas Communications. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in this activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour(s).

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COIs are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Richard A. Elion, MD
Grants/Research support: Gilead Sciences, Inc., ViiV Healthcare
Honoraria: Gilead Sciences, Inc., ViiV Healthcare
Speakers Bureau: Gilead Sciences, Inc.

Eric S. Daar, MD
Consulting Fees: Genentech Inc., Gilead Sciences, Inc., Merck Co., Inc.
Contracted Research: Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare

Seble G. Kassaye, MD, MS
Nothing to disclose

Leandro A. Mena, MD, MPH
Consulting Fees: Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare
Contracted Research: Gilead Sciences, Inc., GlaxoSmithKline, Johnson & Johnson, Merck & Co., Inc., Roche, TaiMed Biologics, ViiV Healthcare

The PIM planners and managers have nothing to disclose. The Integritas Communications planners and managers have nothing to disclose.

Instructions to Receive Credit

There are no fees for participating and receiving CE credit for this activity. Participants must read the learning objectives and faculty disclosures and participate in the educational activity. 

A statement of credit will be issued upon receipt of a completed posttest (with a score of 70% or higher) and an activity evaluation form at the conclusion of the activity.

If you have questions regarding the receipt of your certificate, please contact PIM via email at inquiries@pimed.com.

Media

Internet

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

0.50 CME / CNE
Postgraduate Institute for Medicine
Case in Point™ Case Challenges in HIV Medicine: Benefits, Barriers, & Best Practices in an Advancing Field - Optimizing Adherence and Retention in Care in HIV

Case in Point™ Case Challenges in HIV Medicine: Benefits, Barriers, & Best Practices in an Advancing Field - Optimizing Adherence and Retention in Care in HIV

Start

Activity Details

Free CME/CNE
0.5 AMA PRA Category 1 Credit(s)
0.5 Contact Hour(s)
Released: January 8, 2021
Expires: January 8, 2022
30 minutes to complete

Statement of Commercial Support

Supported by an independent educational grant from Gilead Sciences, Inc.

Provided By

This activity is jointly provided by Postgraduate Institute for Medicine and Integritas Communications.

Target Audience

This activity is designed to educate HIV specialists and infectious disease clinicians who are involved in the management of patients living with HIV.

Learning Objectives

Upon completion of this activity, the participant should be better able to:

  • Optimize ART selection for treatment initiation and medication switching according to patient characteristics and comorbidities

Program Description

In this portion of a previous case-based symposium, Dr. Richard Elion, along with Drs. Eric Daar, Seble Kassaye, and Leandro Mena, will elucidate appropriate treatment approaches that integrate established, streamlined models of care and demonstrate optimal selection of ART. Demonstrating key considerations of HIV management through cases, faculty will identify and discuss aspects of care (e.g., comorbidities, polypharmacy issues, and adverse events) associated with ART regimens in specific subpopulations, such as women or the aging population. The proliferation of treatment-switching strategies has made therapeutic selection increasingly complex; real-world cases can provide context for education on this challenging topic.

Within the context of these interactive cases, faculty will share relevant guideline recommendations, newly published data, and their clinical expertise.

Course Chair

Richard A. Elion, MD
Associate Clinical Professor
Department of Clinical Investigations
Whitman-Walker Health
The George Washington University
Washington, District of Columbia

Dr. Richard Elion is a clinical professor of medicine at George Washington University, as well as Research Director, HIV and HCV Research, at the Washington Health Institute, both in Washington, DC. He is the past Director of Clinical Research at Whitman-Walker Health in Washington, DC, where he focused on cutting-edge research in HIV. His tenure at Whitman-Walker Health coincided with the organization being selected in 2013 as part of the AIDS Clinical Trials Group by the National Institutes of Health. Prior to his tenure with Whitman-Walker Health, he served as Co-Director of HIV Services at Washington Free Clinic in Washington, DC, and in various research and clinical capacities in New York and Washington, DC. In addition to being an accomplished educator and clinician, Dr. Elion also develops educational programs around the United States.

Dr. Elion received his medical degree from Temple University in Philadelphia, Pennsylvania, and completed his internship and residency at Duke University in Durham, North Carolina. He also holds a master’s degree in counseling and spiritual psychology from the University of Santa Monica in Santa Monica, California.

Faculty

Eric S. Daar, MD
Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Chief, HIV Services
Lundquist Institute for Biomedical Innovation
Professor of Medicine, David Geffen School of Medicine
University of California, Los Angeles
Torrance, California

Dr. Eric Daar is Interim Chair of the Department of Medicine and Chief of the Division of HIV Medicine at the Harbor-UCLA Medical Center in Torrance, California. He is also a professor of medicine at the David Geffen School of Medicine at UCLA in Los Angeles, California, as well as an investigator for the Lundquist Institute. He earned his medical degree from Georgetown University School of Medicine in Washington, DC, and completed his internship, residency, and fellowship at Cedars-Sinai Medical Center in Los Angeles. His clinical and research interests include a vast range of HIV-related issues that include pathogenesis and treatment of acute and chronic HIV infection, HIV/HCV coinfection, complications of HIV, and novel strategies for assessing and enhancing adherence to therapy. He has authored numerous articles that have been published in peer-reviewed journals and textbooks.

Seble G. Kassaye, MD, MS
Associate Professor of Medicine
Department of Medicine
Division of Infectious Diseases
Georgetown University
Washington, District of Columbia

Dr. Seble Kassaye earned her medical degree from the University of Chicago Pritzker School of Medicine in Illinois before completing her residency training in internal medicine and pediatrics at Mount Sinai Medical Center in New York and her infectious disease fellowship at Stanford University Hospital in California. She also completed a master’s degree in epidemiology at Stanford University. Dr. Kassaye joined the faculty at Georgetown University in December 2012.

Dr. Kassaye’s investigative focus is on clinical and translational research related to HIV with the objective of increasing access to and uptake of effective HIV treatment and prevention modalities by the most at-risk and indigent populations. As the principal investigator of the DC MACS/WIHS Combined Cohort Study, she aims to understand how HIV contributes to comorbidities, metabolic and cardiovascular complications, and long-term treatment outcomes, along with social, psychological, and cognitive effects of HIV. Dr. Kassaye has been a practicing physician in Washington, DC, for almost a decade, including at a tertiary care academic center as well as a community-based clinic in the ward with highest HIV prevalence in southeast DC. Most of her US-based research projects are driven by questions that she identifies in the context of providing care to a highly indigent and socially vulnerable population.

Leandro A. Mena, MD, MPH
Chair and Professor of Population Health Science
Professor of Medicine, Division of Infectious Diseases
Director, Center for HIV/AIDS Research, Education and Policy
The University of Mississippi Medical Center
Jackson, Mississippi

Dr. Leandro Mena is a clinician-researcher and public health advocate with expertise in the prevention and clinical management of sexually transmitted diseases (STDs) and HIV. He is founding chair of the Department of Population Health Science at the University of Mississippi Medical Center, John D. Bower School of Population Health, and professor of medicine in the Division of Infectious Diseases. He directs the Center for HIV/AIDS Research, Education and Policy at the Myrlie Evers-Williams Institute for Elimination of Health Disparities, and serves as the STD Medical Director for the state of Mississippi. He is also the Medical Director of the Five Points Clinic (Jackson’s public STD clinic) and cofounded Open Arms Healthcare Center (first LGBT clinic in Mississippi).

In recognition of his work developing a model program of culturally competent HIV prevention and care for Black men who have sex with men, which is being replicated in other clinics of the country, he was awarded the 2016 Achievement Award by the Gay and Lesbian Medical Association (GLMA). Board certified in infectious diseases, Dr. Mena is a research fellow with the Rural Center for STD/HIV Prevention (Indiana University). His interests include understanding the dynamics of HIV transmission in racial/ethnic, gender, and sexual minorities as well as the development and provision of culturally competent quality health services to these populations.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Integritas Communications. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in this activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour(s).

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COIs are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Richard A. Elion, MD
Grants/Research support: Gilead Sciences, Inc., ViiV Healthcare
Honoraria: Gilead Sciences, Inc., ViiV Healthcare
Speakers Bureau: Gilead Sciences, Inc.

Eric S. Daar, MD
Consulting Fees: Genentech Inc., Gilead Sciences, Inc., Merck Co., Inc.
Contracted Research: Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare

Seble G. Kassaye, MD, MS
Nothing to disclose

Leandro A. Mena, MD, MPH
Consulting Fees: Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare
Contracted Research: Gilead Sciences, Inc., GlaxoSmithKline, Johnson & Johnson, Merck & Co., Inc., Roche, TaiMed Biologics, ViiV Healthcare

The PIM planners and managers have nothing to disclose. The Integritas Communications planners and managers have nothing to disclose.

Instructions to Receive Credit

There are no fees for participating and receiving CE credit for this activity. Participants must read the learning objectives and faculty disclosures and participate in the educational activity. 

A statement of credit will be issued upon receipt of a completed posttest (with a score of 70% or higher) and an activity evaluation form at the conclusion of the activity.

If you have questions regarding the receipt of your certificate, please contact PIM via email at inquiries@pimed.com.

Media

Internet

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Activity Details

Free CME/CNE
0.5 AMA PRA Category 1 Credit(s)
0.5 Contact Hour(s)
Released: January 8, 2021
Expires: January 8, 2022
30 minutes to complete

Statement of Commercial Support

Supported by an independent educational grant from Gilead Sciences, Inc.

Provided By

This activity is jointly provided by Postgraduate Institute for Medicine and Integritas Communications.

Target Audience

This activity is designed to educate HIV specialists and infectious disease clinicians who are involved in the management of patients living with HIV.

Learning Objectives

Upon completion of this activity, the participant should be better able to:

  • Optimize ART selection for treatment initiation and medication switching according to patient characteristics and comorbidities

Program Description

In this portion of a previous case-based symposium, Dr. Richard Elion, along with Drs. Eric Daar, Seble Kassaye, and Leandro Mena, will elucidate appropriate treatment approaches that integrate established, streamlined models of care and demonstrate optimal selection of ART. Demonstrating key considerations of HIV management through cases, faculty will identify and discuss aspects of care (e.g., comorbidities, polypharmacy issues, and adverse events) associated with ART regimens in specific subpopulations, such as women or the aging population. The proliferation of treatment-switching strategies has made therapeutic selection increasingly complex; real-world cases can provide context for education on this challenging topic.

Within the context of these interactive cases, faculty will share relevant guideline recommendations, newly published data, and their clinical expertise.

Course Chair

Richard A. Elion, MD
Associate Clinical Professor
Department of Clinical Investigations
Whitman-Walker Health
The George Washington University
Washington, District of Columbia

Dr. Richard Elion is a clinical professor of medicine at George Washington University, as well as Research Director, HIV and HCV Research, at the Washington Health Institute, both in Washington, DC. He is the past Director of Clinical Research at Whitman-Walker Health in Washington, DC, where he focused on cutting-edge research in HIV. His tenure at Whitman-Walker Health coincided with the organization being selected in 2013 as part of the AIDS Clinical Trials Group by the National Institutes of Health. Prior to his tenure with Whitman-Walker Health, he served as Co-Director of HIV Services at Washington Free Clinic in Washington, DC, and in various research and clinical capacities in New York and Washington, DC. In addition to being an accomplished educator and clinician, Dr. Elion also develops educational programs around the United States.

Dr. Elion received his medical degree from Temple University in Philadelphia, Pennsylvania, and completed his internship and residency at Duke University in Durham, North Carolina. He also holds a master’s degree in counseling and spiritual psychology from the University of Santa Monica in Santa Monica, California.

Faculty

Eric S. Daar, MD
Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Chief, HIV Services
Lundquist Institute for Biomedical Innovation
Professor of Medicine, David Geffen School of Medicine
University of California, Los Angeles
Torrance, California

Dr. Eric Daar is Interim Chair of the Department of Medicine and Chief of the Division of HIV Medicine at the Harbor-UCLA Medical Center in Torrance, California. He is also a professor of medicine at the David Geffen School of Medicine at UCLA in Los Angeles, California, as well as an investigator for the Lundquist Institute. He earned his medical degree from Georgetown University School of Medicine in Washington, DC, and completed his internship, residency, and fellowship at Cedars-Sinai Medical Center in Los Angeles. His clinical and research interests include a vast range of HIV-related issues that include pathogenesis and treatment of acute and chronic HIV infection, HIV/HCV coinfection, complications of HIV, and novel strategies for assessing and enhancing adherence to therapy. He has authored numerous articles that have been published in peer-reviewed journals and textbooks.

Seble G. Kassaye, MD, MS
Associate Professor of Medicine
Department of Medicine
Division of Infectious Diseases
Georgetown University
Washington, District of Columbia

Dr. Seble Kassaye earned her medical degree from the University of Chicago Pritzker School of Medicine in Illinois before completing her residency training in internal medicine and pediatrics at Mount Sinai Medical Center in New York and her infectious disease fellowship at Stanford University Hospital in California. She also completed a master’s degree in epidemiology at Stanford University. Dr. Kassaye joined the faculty at Georgetown University in December 2012.

Dr. Kassaye’s investigative focus is on clinical and translational research related to HIV with the objective of increasing access to and uptake of effective HIV treatment and prevention modalities by the most at-risk and indigent populations. As the principal investigator of the DC MACS/WIHS Combined Cohort Study, she aims to understand how HIV contributes to comorbidities, metabolic and cardiovascular complications, and long-term treatment outcomes, along with social, psychological, and cognitive effects of HIV. Dr. Kassaye has been a practicing physician in Washington, DC, for almost a decade, including at a tertiary care academic center as well as a community-based clinic in the ward with highest HIV prevalence in southeast DC. Most of her US-based research projects are driven by questions that she identifies in the context of providing care to a highly indigent and socially vulnerable population.

Leandro A. Mena, MD, MPH
Chair and Professor of Population Health Science
Professor of Medicine, Division of Infectious Diseases
Director, Center for HIV/AIDS Research, Education and Policy
The University of Mississippi Medical Center
Jackson, Mississippi

Dr. Leandro Mena is a clinician-researcher and public health advocate with expertise in the prevention and clinical management of sexually transmitted diseases (STDs) and HIV. He is founding chair of the Department of Population Health Science at the University of Mississippi Medical Center, John D. Bower School of Population Health, and professor of medicine in the Division of Infectious Diseases. He directs the Center for HIV/AIDS Research, Education and Policy at the Myrlie Evers-Williams Institute for Elimination of Health Disparities, and serves as the STD Medical Director for the state of Mississippi. He is also the Medical Director of the Five Points Clinic (Jackson’s public STD clinic) and cofounded Open Arms Healthcare Center (first LGBT clinic in Mississippi).

In recognition of his work developing a model program of culturally competent HIV prevention and care for Black men who have sex with men, which is being replicated in other clinics of the country, he was awarded the 2016 Achievement Award by the Gay and Lesbian Medical Association (GLMA). Board certified in infectious diseases, Dr. Mena is a research fellow with the Rural Center for STD/HIV Prevention (Indiana University). His interests include understanding the dynamics of HIV transmission in racial/ethnic, gender, and sexual minorities as well as the development and provision of culturally competent quality health services to these populations.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Integritas Communications. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in this activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour(s).

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COIs are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Richard A. Elion, MD
Grants/Research support: Gilead Sciences, Inc., ViiV Healthcare
Honoraria: Gilead Sciences, Inc., ViiV Healthcare
Speakers Bureau: Gilead Sciences, Inc.

Eric S. Daar, MD
Consulting Fees: Genentech Inc., Gilead Sciences, Inc., Merck Co., Inc.
Contracted Research: Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare

Seble G. Kassaye, MD, MS
Nothing to disclose

Leandro A. Mena, MD, MPH
Consulting Fees: Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare
Contracted Research: Gilead Sciences, Inc., GlaxoSmithKline, Johnson & Johnson, Merck & Co., Inc., Roche, TaiMed Biologics, ViiV Healthcare

The PIM planners and managers have nothing to disclose. The Integritas Communications planners and managers have nothing to disclose.

Instructions to Receive Credit

There are no fees for participating and receiving CE credit for this activity. Participants must read the learning objectives and faculty disclosures and participate in the educational activity. 

A statement of credit will be issued upon receipt of a completed posttest (with a score of 70% or higher) and an activity evaluation form at the conclusion of the activity.

If you have questions regarding the receipt of your certificate, please contact PIM via email at inquiries@pimed.com.

Media

Internet

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

0.50 CME / CNE
Postgraduate Institute for Medicine
Case in Point™ Case Challenges in HIV Medicine: Benefits, Barriers, & Best Practices in an Advancing Field - Guideline Updates and Recent Therapeutic Advances in HIV

Case in Point™ Case Challenges in HIV Medicine: Benefits, Barriers, & Best Practices in an Advancing Field - Guideline Updates and Recent Therapeutic Advances in HIV

Start

Activity Details

Free CME/CNE
0.5 AMA PRA Category 1 Credit(s)
0.5 Contact Hour(s)
Released: January 8, 2021
Expires: January 8, 2022
30 minutes to complete

Statement of Commercial Support

Supported by an independent educational grant from Gilead Sciences, Inc.

Provided By

This activity is jointly provided by Postgraduate Institute for Medicine and Integritas Communications.

Target Audience

This activity is designed to educate HIV specialists and infectious disease clinicians who are involved in the management of patients living with HIV.

Learning Objectives

Upon completion of this activity, the participant should be better able to:

  • Implement the most recent guidelines on identifying, treating, and monitoring patients with HIV
  • Optimize ART selection for treatment initiation and medication switching according to patient characteristics and comorbidities

Program Description

In this portion of a previous case-based symposium, Dr. Richard Elion, along with Drs. Eric Daar, Seble Kassaye, and Leandro Mena, will elucidate appropriate treatment approaches that integrate established, streamlined models of care and demonstrate optimal selection of ART. Demonstrating key considerations of HIV management through cases, faculty will identify and discuss aspects of care (e.g., comorbidities, polypharmacy issues, and adverse events) associated with ART regimens that may necessitate a switch to 2-drug regimens. Risks and benefits of initiating treatment with a 2-drug regimen will be discussed. As HIV care progresses and new treatment options become available for initiating and switching ART regimens, clinicians must know the data, indications, contraindications, and potential for adverse events or drug-drug interactions when individualizing treatment plans.

Within the context of these interactive cases, faculty will share relevant guideline recommendations, newly published data, and their clinical expertise.

Course Chair

Richard A. Elion, MD
Associate Clinical Professor
Department of Clinical Investigations
Whitman-Walker Health
The George Washington University
Washington, District of Columbia

Dr. Richard Elion is a clinical professor of medicine at George Washington University, as well as Research Director, HIV and HCV Research, at the Washington Health Institute, both in Washington, DC. He is the past Director of Clinical Research at Whitman-Walker Health in Washington, DC, where he focused on cutting-edge research in HIV. His tenure at Whitman-Walker Health coincided with the organization being selected in 2013 as part of the AIDS Clinical Trials Group by the National Institutes of Health. Prior to his tenure with Whitman-Walker Health, he served as Co-Director of HIV Services at Washington Free Clinic in Washington, DC, and in various research and clinical capacities in New York and Washington, DC. In addition to being an accomplished educator and clinician, Dr. Elion also develops educational programs around the United States.

Dr. Elion received his medical degree from Temple University in Philadelphia, Pennsylvania, and completed his internship and residency at Duke University in Durham, North Carolina. He also holds a master’s degree in counseling and spiritual psychology from the University of Santa Monica in Santa Monica, California.

Faculty

Eric S. Daar, MD
Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Chief, HIV Services
Lundquist Institute for Biomedical Innovation
Professor of Medicine, David Geffen School of Medicine
University of California, Los Angeles
Torrance, California

Dr. Eric Daar is Interim Chair of the Department of Medicine and Chief of the Division of HIV Medicine at the Harbor-UCLA Medical Center in Torrance, California. He is also a professor of medicine at the David Geffen School of Medicine at UCLA in Los Angeles, California, as well as an investigator for the Lundquist Institute. He earned his medical degree from Georgetown University School of Medicine in Washington, DC, and completed his internship, residency, and fellowship at Cedars-Sinai Medical Center in Los Angeles. His clinical and research interests include a vast range of HIV-related issues that include pathogenesis and treatment of acute and chronic HIV infection, HIV/HCV coinfection, complications of HIV, and novel strategies for assessing and enhancing adherence to therapy. He has authored numerous articles that have been published in peer-reviewed journals and textbooks.

Seble G. Kassaye, MD, MS
Associate Professor of Medicine
Department of Medicine
Division of Infectious Diseases
Georgetown University
Washington, District of Columbia

Dr. Seble Kassaye earned her medical degree from the University of Chicago Pritzker School of Medicine in Illinois before completing her residency training in internal medicine and pediatrics at Mount Sinai Medical Center in New York and her infectious disease fellowship at Stanford University Hospital in California. She also completed a master’s degree in epidemiology at Stanford University. Dr. Kassaye joined the faculty at Georgetown University in December 2012.

Dr. Kassaye’s investigative focus is on clinical and translational research related to HIV with the objective of increasing access to and uptake of effective HIV treatment and prevention modalities by the most at-risk and indigent populations. As the principal investigator of the DC MACS/WIHS Combined Cohort Study, she aims to understand how HIV contributes to comorbidities, metabolic and cardiovascular complications, and long-term treatment outcomes, along with social, psychological, and cognitive effects of HIV. Dr. Kassaye has been a practicing physician in Washington, DC, for almost a decade, including at a tertiary care academic center as well as a community-based clinic in the ward with highest HIV prevalence in southeast DC. Most of her US-based research projects are driven by questions that she identifies in the context of providing care to a highly indigent and socially vulnerable population.

Leandro A. Mena, MD, MPH
Chair and Professor of Population Health Science
Professor of Medicine, Division of Infectious Diseases
Director, Center for HIV/AIDS Research, Education and Policy
The University of Mississippi Medical Center
Jackson, Mississippi

Dr. Leandro Mena is a clinician-researcher and public health advocate with expertise in the prevention and clinical management of sexually transmitted diseases (STDs) and HIV. He is founding chair of the Department of Population Health Science at the University of Mississippi Medical Center, John D. Bower School of Population Health, and professor of medicine in the Division of Infectious Diseases. He directs the Center for HIV/AIDS Research, Education and Policy at the Myrlie Evers-Williams Institute for Elimination of Health Disparities, and serves as the STD Medical Director for the state of Mississippi. He is also the Medical Director of the Five Points Clinic (Jackson’s public STD clinic) and cofounded Open Arms Healthcare Center (first LGBT clinic in Mississippi).

In recognition of his work developing a model program of culturally competent HIV prevention and care for Black men who have sex with men, which is being replicated in other clinics of the country, he was awarded the 2016 Achievement Award by the Gay and Lesbian Medical Association (GLMA). Board certified in infectious diseases, Dr. Mena is a research fellow with the Rural Center for STD/HIV Prevention (Indiana University). His interests include understanding the dynamics of HIV transmission in racial/ethnic, gender, and sexual minorities as well as the development and provision of culturally competent quality health services to these populations.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Integritas Communications. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in this activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour(s).

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COIs are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Richard A. Elion, MD
Grants/Research support: Gilead Sciences, Inc., ViiV Healthcare
Honoraria: Gilead Sciences, Inc., ViiV Healthcare
Speakers Bureau: Gilead Sciences, Inc.

Eric S. Daar, MD
Consulting Fees: Genentech Inc., Gilead Sciences, Inc., Merck Co., Inc.
Contracted Research: Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare

Seble G. Kassaye, MD, MS
Nothing to disclose

Leandro A. Mena, MD, MPH
Consulting Fees: Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare
Contracted Research: Gilead Sciences, Inc., GlaxoSmithKline, Johnson & Johnson, Merck & Co., Inc., Roche, TaiMed Biologics, ViiV Healthcare

The PIM planners and managers have nothing to disclose. The Integritas Communications planners and managers have nothing to disclose.

Instructions to Receive Credit

There are no fees for participating and receiving CE credit for this activity. Participants must read the learning objectives and faculty disclosures and participate in the educational activity. 

A statement of credit will be issued upon receipt of a completed posttest (with a score of 70% or higher) and an activity evaluation form at the conclusion of the activity.

If you have questions regarding the receipt of your certificate, please contact PIM via email at inquiries@pimed.com.

Media

Internet

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Activity Details

Free CME/CNE
0.5 AMA PRA Category 1 Credit(s)
0.5 Contact Hour(s)
Released: January 8, 2021
Expires: January 8, 2022
30 minutes to complete

Statement of Commercial Support

Supported by an independent educational grant from Gilead Sciences, Inc.

Provided By

This activity is jointly provided by Postgraduate Institute for Medicine and Integritas Communications.

Target Audience

This activity is designed to educate HIV specialists and infectious disease clinicians who are involved in the management of patients living with HIV.

Learning Objectives

Upon completion of this activity, the participant should be better able to:

  • Implement the most recent guidelines on identifying, treating, and monitoring patients with HIV
  • Optimize ART selection for treatment initiation and medication switching according to patient characteristics and comorbidities

Program Description

In this portion of a previous case-based symposium, Dr. Richard Elion, along with Drs. Eric Daar, Seble Kassaye, and Leandro Mena, will elucidate appropriate treatment approaches that integrate established, streamlined models of care and demonstrate optimal selection of ART. Demonstrating key considerations of HIV management through cases, faculty will identify and discuss aspects of care (e.g., comorbidities, polypharmacy issues, and adverse events) associated with ART regimens that may necessitate a switch to 2-drug regimens. Risks and benefits of initiating treatment with a 2-drug regimen will be discussed. As HIV care progresses and new treatment options become available for initiating and switching ART regimens, clinicians must know the data, indications, contraindications, and potential for adverse events or drug-drug interactions when individualizing treatment plans.

Within the context of these interactive cases, faculty will share relevant guideline recommendations, newly published data, and their clinical expertise.

Course Chair

Richard A. Elion, MD
Associate Clinical Professor
Department of Clinical Investigations
Whitman-Walker Health
The George Washington University
Washington, District of Columbia

Dr. Richard Elion is a clinical professor of medicine at George Washington University, as well as Research Director, HIV and HCV Research, at the Washington Health Institute, both in Washington, DC. He is the past Director of Clinical Research at Whitman-Walker Health in Washington, DC, where he focused on cutting-edge research in HIV. His tenure at Whitman-Walker Health coincided with the organization being selected in 2013 as part of the AIDS Clinical Trials Group by the National Institutes of Health. Prior to his tenure with Whitman-Walker Health, he served as Co-Director of HIV Services at Washington Free Clinic in Washington, DC, and in various research and clinical capacities in New York and Washington, DC. In addition to being an accomplished educator and clinician, Dr. Elion also develops educational programs around the United States.

Dr. Elion received his medical degree from Temple University in Philadelphia, Pennsylvania, and completed his internship and residency at Duke University in Durham, North Carolina. He also holds a master’s degree in counseling and spiritual psychology from the University of Santa Monica in Santa Monica, California.

Faculty

Eric S. Daar, MD
Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Chief, HIV Services
Lundquist Institute for Biomedical Innovation
Professor of Medicine, David Geffen School of Medicine
University of California, Los Angeles
Torrance, California

Dr. Eric Daar is Interim Chair of the Department of Medicine and Chief of the Division of HIV Medicine at the Harbor-UCLA Medical Center in Torrance, California. He is also a professor of medicine at the David Geffen School of Medicine at UCLA in Los Angeles, California, as well as an investigator for the Lundquist Institute. He earned his medical degree from Georgetown University School of Medicine in Washington, DC, and completed his internship, residency, and fellowship at Cedars-Sinai Medical Center in Los Angeles. His clinical and research interests include a vast range of HIV-related issues that include pathogenesis and treatment of acute and chronic HIV infection, HIV/HCV coinfection, complications of HIV, and novel strategies for assessing and enhancing adherence to therapy. He has authored numerous articles that have been published in peer-reviewed journals and textbooks.

Seble G. Kassaye, MD, MS
Associate Professor of Medicine
Department of Medicine
Division of Infectious Diseases
Georgetown University
Washington, District of Columbia

Dr. Seble Kassaye earned her medical degree from the University of Chicago Pritzker School of Medicine in Illinois before completing her residency training in internal medicine and pediatrics at Mount Sinai Medical Center in New York and her infectious disease fellowship at Stanford University Hospital in California. She also completed a master’s degree in epidemiology at Stanford University. Dr. Kassaye joined the faculty at Georgetown University in December 2012.

Dr. Kassaye’s investigative focus is on clinical and translational research related to HIV with the objective of increasing access to and uptake of effective HIV treatment and prevention modalities by the most at-risk and indigent populations. As the principal investigator of the DC MACS/WIHS Combined Cohort Study, she aims to understand how HIV contributes to comorbidities, metabolic and cardiovascular complications, and long-term treatment outcomes, along with social, psychological, and cognitive effects of HIV. Dr. Kassaye has been a practicing physician in Washington, DC, for almost a decade, including at a tertiary care academic center as well as a community-based clinic in the ward with highest HIV prevalence in southeast DC. Most of her US-based research projects are driven by questions that she identifies in the context of providing care to a highly indigent and socially vulnerable population.

Leandro A. Mena, MD, MPH
Chair and Professor of Population Health Science
Professor of Medicine, Division of Infectious Diseases
Director, Center for HIV/AIDS Research, Education and Policy
The University of Mississippi Medical Center
Jackson, Mississippi

Dr. Leandro Mena is a clinician-researcher and public health advocate with expertise in the prevention and clinical management of sexually transmitted diseases (STDs) and HIV. He is founding chair of the Department of Population Health Science at the University of Mississippi Medical Center, John D. Bower School of Population Health, and professor of medicine in the Division of Infectious Diseases. He directs the Center for HIV/AIDS Research, Education and Policy at the Myrlie Evers-Williams Institute for Elimination of Health Disparities, and serves as the STD Medical Director for the state of Mississippi. He is also the Medical Director of the Five Points Clinic (Jackson’s public STD clinic) and cofounded Open Arms Healthcare Center (first LGBT clinic in Mississippi).

In recognition of his work developing a model program of culturally competent HIV prevention and care for Black men who have sex with men, which is being replicated in other clinics of the country, he was awarded the 2016 Achievement Award by the Gay and Lesbian Medical Association (GLMA). Board certified in infectious diseases, Dr. Mena is a research fellow with the Rural Center for STD/HIV Prevention (Indiana University). His interests include understanding the dynamics of HIV transmission in racial/ethnic, gender, and sexual minorities as well as the development and provision of culturally competent quality health services to these populations.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Integritas Communications. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in this activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour(s).

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COIs are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Richard A. Elion, MD
Grants/Research support: Gilead Sciences, Inc., ViiV Healthcare
Honoraria: Gilead Sciences, Inc., ViiV Healthcare
Speakers Bureau: Gilead Sciences, Inc.

Eric S. Daar, MD
Consulting Fees: Genentech Inc., Gilead Sciences, Inc., Merck Co., Inc.
Contracted Research: Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare

Seble G. Kassaye, MD, MS
Nothing to disclose

Leandro A. Mena, MD, MPH
Consulting Fees: Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare
Contracted Research: Gilead Sciences, Inc., GlaxoSmithKline, Johnson & Johnson, Merck & Co., Inc., Roche, TaiMed Biologics, ViiV Healthcare

The PIM planners and managers have nothing to disclose. The Integritas Communications planners and managers have nothing to disclose.

Instructions to Receive Credit

There are no fees for participating and receiving CE credit for this activity. Participants must read the learning objectives and faculty disclosures and participate in the educational activity. 

A statement of credit will be issued upon receipt of a completed posttest (with a score of 70% or higher) and an activity evaluation form at the conclusion of the activity.

If you have questions regarding the receipt of your certificate, please contact PIM via email at inquiries@pimed.com.

Media

Internet

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

0.25 CME / MOC
Global Education Group
Fire Fight: Smothering the Flame of Type 2 Inflammation ̶ Patient with Asthma Requiring Step-up Therapy

Fire Fight: Smothering the Flame of Type 2 Inflammation ̶ Patient with Asthma Requiring Step-up Therapy

Start

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)™/
MOC Point(s)
Released: December 21, 2020
Expires: December 20, 2021
15 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and RMEI Medical Education, LLC.

Target Audience

The educational design of this activity addresses the needs of physicians who specialize in allergy/immunology, dermatology, otolaryngology, pulmonology, and primary care.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Identify patients with type 2 inflammatory diseases who are eligible for step-up therapies, including new and emerging biologics
  • Describe how to work with a multidisciplinary team to develop a treatment strategy for patients with multiple coexisting atopic diseases

Activity Description

In this interactive panel discussion, 3 multidisciplinary clinical opinion leaders discuss management solutions for a real-world asthma patient case that was selected from a community-based clinician submission.

Statement of Educational Need

Advances in understanding the pathophysiology of atopic diseases highlight the importance and commonality of underlying type 2 inflammation in a range of diseases like asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps. Key drivers of type 2 inflammation have been identified, with IL-4 and IL-13 playing a central role. In the last few years, biologics targeting type 2 inflammation have emerged as effective treatment options for patients with atopic diseases, particularly in people with moderate-to-severe disease. Because of the relative novelty of these treatments, healthcare professionals should be aware of the pathophysiology of disease, as well as the efficacy, safety, and tolerability of biologics, the rationale for use, and how to incorporate these treatments into management of appropriate patients. 

Faculty

Peter A. Lio, MD, FAAD
Clinical Assistant Professor, Dermatology & Pediatrics
Northwestern University Feinberg School of Medicine
Chicago, IL


Joseph K. Han, MD
Professor, EVMS
Chief, Division of Rhinology and Endoscopic Sinus-Skull Base Surgery
Chief, Division of Allergy
President Elect, ARS
Chair Elect, AAAAI, RROAC
Eastern Virginia Medical School
Norfolk, VA


Anju T. Peters, MD, MS
Professor, Medicine
Division of Allergy-Immunology
Director, Clinical Research
Northwestern University Feinberg School of Medicine
Chicago, IL


Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Peter Lio, MD, FAAD
Consultant/Independent Contractor: AbbVie, Amyris, AOBiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Grant/Research Support: AbbVie, National Eczema Association, Regeneron/Sanofi Genzyme.
Honoraria: AbbVie, Amyris, AObiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Speaker’s Bureau: Galderma, L’Oréal, Pfizer, Regeneron/Sanofi Genzyme.
Advisory Board: AbbVie, Amyris, AOBiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Stock Shareholder: Altus Labs, Micreos, YoBee.
Other Royalty: Theraplex AIM (OTC product) Royalties. 

Joseph K. Han, MD
Consultant/Independent Contractor: AstraZeneca, Genentech, GlaxoSmithKline, Novartis, Sanofi Regeneron.

Anju T. Peters, MD, MS
Grant/Research Support: AstraZeneca, Optinose (Research Support is to Institution)
Advisory Board: AstraZeneca, GlaxoSmithKline, Optinose, Sanofi Regeneron.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Lindsay Borvansky has nothing to disclose.
Andrea Funk has nothing to disclose.
Liddy Knight has nothing to disclose.
Ashley Cann has nothing to disclose.
Deborah Liao has nothing to disclose.
Sharon Powell has nothing to disclose.
Elizabeth Johnson has nothing to disclose. 

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and RMEI Medical Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians. 

Physician Credit Designation

Global Education Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

There is no fee for this educational activity. 

This activity was released on December 21, 2020 and is valid for one year. Requests for credit must be made no later than December 20, 2021.

In order to receive credit for this activity, the participant must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity post-test (score 75% or higher) and evaluation.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals. 

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and RMEI Medical Education, LLC do not recommend the use of any agent outside of the labeled indications.   

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Contact Information for Questions About the Activity

For information about the accreditation of this program, please contact Global Education Group at 303-395-1782 or cme@globaleducationgroup.com. 

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)™/
MOC Point(s)
Released: December 21, 2020
Expires: December 20, 2021
15 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and RMEI Medical Education, LLC.

Target Audience

The educational design of this activity addresses the needs of physicians who specialize in allergy/immunology, dermatology, otolaryngology, pulmonology, and primary care.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Identify patients with type 2 inflammatory diseases who are eligible for step-up therapies, including new and emerging biologics
  • Describe how to work with a multidisciplinary team to develop a treatment strategy for patients with multiple coexisting atopic diseases

Activity Description

In this interactive panel discussion, 3 multidisciplinary clinical opinion leaders discuss management solutions for a real-world asthma patient case that was selected from a community-based clinician submission.

Statement of Educational Need

Advances in understanding the pathophysiology of atopic diseases highlight the importance and commonality of underlying type 2 inflammation in a range of diseases like asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps. Key drivers of type 2 inflammation have been identified, with IL-4 and IL-13 playing a central role. In the last few years, biologics targeting type 2 inflammation have emerged as effective treatment options for patients with atopic diseases, particularly in people with moderate-to-severe disease. Because of the relative novelty of these treatments, healthcare professionals should be aware of the pathophysiology of disease, as well as the efficacy, safety, and tolerability of biologics, the rationale for use, and how to incorporate these treatments into management of appropriate patients. 

Faculty

Peter A. Lio, MD, FAAD
Clinical Assistant Professor, Dermatology & Pediatrics
Northwestern University Feinberg School of Medicine
Chicago, IL


Joseph K. Han, MD
Professor, EVMS
Chief, Division of Rhinology and Endoscopic Sinus-Skull Base Surgery
Chief, Division of Allergy
President Elect, ARS
Chair Elect, AAAAI, RROAC
Eastern Virginia Medical School
Norfolk, VA


Anju T. Peters, MD, MS
Professor, Medicine
Division of Allergy-Immunology
Director, Clinical Research
Northwestern University Feinberg School of Medicine
Chicago, IL


Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Peter Lio, MD, FAAD
Consultant/Independent Contractor: AbbVie, Amyris, AOBiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Grant/Research Support: AbbVie, National Eczema Association, Regeneron/Sanofi Genzyme.
Honoraria: AbbVie, Amyris, AObiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Speaker’s Bureau: Galderma, L’Oréal, Pfizer, Regeneron/Sanofi Genzyme.
Advisory Board: AbbVie, Amyris, AOBiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Stock Shareholder: Altus Labs, Micreos, YoBee.
Other Royalty: Theraplex AIM (OTC product) Royalties. 

Joseph K. Han, MD
Consultant/Independent Contractor: AstraZeneca, Genentech, GlaxoSmithKline, Novartis, Sanofi Regeneron.

Anju T. Peters, MD, MS
Grant/Research Support: AstraZeneca, Optinose (Research Support is to Institution)
Advisory Board: AstraZeneca, GlaxoSmithKline, Optinose, Sanofi Regeneron.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Lindsay Borvansky has nothing to disclose.
Andrea Funk has nothing to disclose.
Liddy Knight has nothing to disclose.
Ashley Cann has nothing to disclose.
Deborah Liao has nothing to disclose.
Sharon Powell has nothing to disclose.
Elizabeth Johnson has nothing to disclose. 

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and RMEI Medical Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians. 

Physician Credit Designation

Global Education Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

There is no fee for this educational activity. 

This activity was released on December 21, 2020 and is valid for one year. Requests for credit must be made no later than December 20, 2021.

In order to receive credit for this activity, the participant must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity post-test (score 75% or higher) and evaluation.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals. 

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and RMEI Medical Education, LLC do not recommend the use of any agent outside of the labeled indications.   

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Contact Information for Questions About the Activity

For information about the accreditation of this program, please contact Global Education Group at 303-395-1782 or cme@globaleducationgroup.com. 

0.25 CME / MOC
Global Education Group
Fire Fight: Smothering the Flame of Type 2 Inflammation ̶ Patient with Chronic Rhinosinusitis with Nasal Polyps and Comorbid Asthma

Fire Fight: Smothering the Flame of Type 2 Inflammation ̶ Patient with Chronic Rhinosinusitis with Nasal Polyps and Comorbid Asthma

Start

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)™/
MOC Point(s)
Released: December 21, 2020
Expires: December 20, 2021
15 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and RMEI Medical Education, LLC.

Target Audience

The educational design of this activity addresses the needs of physicians who specialize in allergy/immunology, dermatology, otolaryngology, pulmonology, and primary care.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Identify patients with type 2 inflammatory diseases who are eligible for step-up therapies, including new and emerging biologics
  • Describe how to evaluate quality-of-life issues and psychosocial comorbidities in patients with atopic diseases

Activity Description

In this interactive panel discussion, 3 multidisciplinary clinical opinion leaders discuss management solutions for a real-world chronic rhinosinusitis with nasal polyps patient case that was selected from a community-based clinician submission.

Statement of Educational Need

Advances in understanding the pathophysiology of atopic diseases highlight the importance and commonality of underlying type 2 inflammation in a range of diseases like asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps. Key drivers of type 2 inflammation have been identified, with IL-4 and IL-13 playing a central role. In the last few years, biologics targeting type 2 inflammation have emerged as effective treatment options for patients with atopic diseases, particularly in people with moderate-to-severe disease. Because of the relative novelty of these treatments, healthcare professionals should be aware of the pathophysiology of disease, as well as the efficacy, safety, and tolerability of biologics, the rationale for use, and how to incorporate these treatments into management of appropriate patients. 

Faculty

Peter A. Lio, MD, FAAD
Clinical Assistant Professor, Dermatology & Pediatrics
Northwestern University Feinberg School of Medicine
Chicago, IL


Joseph K. Han, MD
Professor, EVMS
Chief, Division of Rhinology and Endoscopic Sinus-Skull Base Surgery
Chief, Division of Allergy
President Elect, ARS
Chair Elect, AAAAI, RROAC
Eastern Virginia Medical School
Norfolk, VA


Anju T. Peters, MD, MS
Professor, Medicine
Division of Allergy-Immunology
Director, Clinical Research
Northwestern University Feinberg School of Medicine
Chicago, IL


Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Peter Lio, MD, FAAD
Consultant/Independent Contractor: AbbVie, Amyris, AOBiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Grant/Research Support: AbbVie, National Eczema Association, Regeneron/Sanofi Genzyme.
Honoraria: AbbVie, Amyris, AObiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Speaker’s Bureau: Galderma, L’Oréal, Pfizer, Regeneron/Sanofi Genzyme.
Advisory Board: AbbVie, Amyris, AOBiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Stock Shareholder: Altus Labs, Micreos, YoBee.
Other Royalty: Theraplex AIM (OTC product) Royalties. 

Joseph K. Han, MD
Consultant/Independent Contractor: AstraZeneca, Genentech, GlaxoSmithKline, Novartis, Sanofi Regeneron.

Anju T. Peters, MD, MS
Grant/Research Support: AstraZeneca, Optinose (Research Support is to Institution)
Advisory Board: AstraZeneca, GlaxoSmithKline, Optinose, Sanofi Regeneron.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Lindsay Borvansky has nothing to disclose.
Andrea Funk has nothing to disclose.
Liddy Knight has nothing to disclose.
Ashley Cann has nothing to disclose.
Deborah Liao has nothing to disclose.
Sharon Powell has nothing to disclose.
Elizabeth Johnson has nothing to disclose. 

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and RMEI Medical Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians. 

Physician Credit Designation

Global Education Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

There is no fee for this educational activity. 

This activity was released on December 21, 2020 and is valid for one year. Requests for credit must be made no later than December 20, 2021.

In order to receive credit for this activity, the participant must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity post-test (score 75% or higher) and evaluation.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals. 

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and RMEI Medical Education, LLC do not recommend the use of any agent outside of the labeled indications.   

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Contact Information for Questions About the Activity

For information about the accreditation of this program, please contact Global Education Group at 303-395-1782 or cme@globaleducationgroup.com. 

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)™/
MOC Point(s)
Released: December 21, 2020
Expires: December 20, 2021
15 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and RMEI Medical Education, LLC.

Target Audience

The educational design of this activity addresses the needs of physicians who specialize in allergy/immunology, dermatology, otolaryngology, pulmonology, and primary care.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Identify patients with type 2 inflammatory diseases who are eligible for step-up therapies, including new and emerging biologics
  • Describe how to evaluate quality-of-life issues and psychosocial comorbidities in patients with atopic diseases

Activity Description

In this interactive panel discussion, 3 multidisciplinary clinical opinion leaders discuss management solutions for a real-world chronic rhinosinusitis with nasal polyps patient case that was selected from a community-based clinician submission.

Statement of Educational Need

Advances in understanding the pathophysiology of atopic diseases highlight the importance and commonality of underlying type 2 inflammation in a range of diseases like asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps. Key drivers of type 2 inflammation have been identified, with IL-4 and IL-13 playing a central role. In the last few years, biologics targeting type 2 inflammation have emerged as effective treatment options for patients with atopic diseases, particularly in people with moderate-to-severe disease. Because of the relative novelty of these treatments, healthcare professionals should be aware of the pathophysiology of disease, as well as the efficacy, safety, and tolerability of biologics, the rationale for use, and how to incorporate these treatments into management of appropriate patients. 

Faculty

Peter A. Lio, MD, FAAD
Clinical Assistant Professor, Dermatology & Pediatrics
Northwestern University Feinberg School of Medicine
Chicago, IL


Joseph K. Han, MD
Professor, EVMS
Chief, Division of Rhinology and Endoscopic Sinus-Skull Base Surgery
Chief, Division of Allergy
President Elect, ARS
Chair Elect, AAAAI, RROAC
Eastern Virginia Medical School
Norfolk, VA


Anju T. Peters, MD, MS
Professor, Medicine
Division of Allergy-Immunology
Director, Clinical Research
Northwestern University Feinberg School of Medicine
Chicago, IL


Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Peter Lio, MD, FAAD
Consultant/Independent Contractor: AbbVie, Amyris, AOBiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Grant/Research Support: AbbVie, National Eczema Association, Regeneron/Sanofi Genzyme.
Honoraria: AbbVie, Amyris, AObiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Speaker’s Bureau: Galderma, L’Oréal, Pfizer, Regeneron/Sanofi Genzyme.
Advisory Board: AbbVie, Amyris, AOBiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Stock Shareholder: Altus Labs, Micreos, YoBee.
Other Royalty: Theraplex AIM (OTC product) Royalties. 

Joseph K. Han, MD
Consultant/Independent Contractor: AstraZeneca, Genentech, GlaxoSmithKline, Novartis, Sanofi Regeneron.

Anju T. Peters, MD, MS
Grant/Research Support: AstraZeneca, Optinose (Research Support is to Institution)
Advisory Board: AstraZeneca, GlaxoSmithKline, Optinose, Sanofi Regeneron.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Lindsay Borvansky has nothing to disclose.
Andrea Funk has nothing to disclose.
Liddy Knight has nothing to disclose.
Ashley Cann has nothing to disclose.
Deborah Liao has nothing to disclose.
Sharon Powell has nothing to disclose.
Elizabeth Johnson has nothing to disclose. 

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and RMEI Medical Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians. 

Physician Credit Designation

Global Education Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

There is no fee for this educational activity. 

This activity was released on December 21, 2020 and is valid for one year. Requests for credit must be made no later than December 20, 2021.

In order to receive credit for this activity, the participant must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity post-test (score 75% or higher) and evaluation.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals. 

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and RMEI Medical Education, LLC do not recommend the use of any agent outside of the labeled indications.   

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Contact Information for Questions About the Activity

For information about the accreditation of this program, please contact Global Education Group at 303-395-1782 or cme@globaleducationgroup.com. 

0.25 CME / MOC
Global Education Group
Fire Fight: Smothering the Flame of Type 2 Inflammation ̶ Patient with Asthma and Atopic Dermatitis and Treatment-Related Conjunctivitis

Fire Fight: Smothering the Flame of Type 2 Inflammation ̶ Patient with Asthma and Atopic Dermatitis and Treatment-Related Conjunctivitis

Start

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)™/
MOC Point(s)
Released: December 21, 2020
Expires: December 20, 2021
15 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and RMEI Medical Education, LLC.

Target Audience

The educational design of this activity addresses the needs of physicians who specialize in allergy/immunology, dermatology, otolaryngology, pulmonology, and primary care.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Recognize adverse events related to biologics used to treat atopic diseases
  • Describe how to work with a multidisciplinary team to develop a treatment strategy for patients with multiple coexisting atopic diseases

Activity Description

In this interactive panel discussion, 3 multidisciplinary clinical opinion leaders discuss management solutions for a real-world atopic dermatitis patient case that was selected from a community-based clinician submission.

Statement of Educational Need

Advances in understanding the pathophysiology of atopic diseases highlight the importance and commonality of underlying type 2 inflammation in a range of diseases like asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps. Key drivers of type 2 inflammation have been identified, with IL-4 and IL-13 playing a central role. In the last few years, biologics targeting type 2 inflammation have emerged as effective treatment options for patients with atopic diseases, particularly in people with moderate-to-severe disease. Because of the relative novelty of these treatments, healthcare professionals should be aware of the pathophysiology of disease, as well as the efficacy, safety, and tolerability of biologics, the rationale for use, and how to incorporate these treatments into management of appropriate patients. 

Faculty

Peter A. Lio, MD, FAAD
Clinical Assistant Professor, Dermatology & Pediatrics
Northwestern University Feinberg School of Medicine
Chicago, IL


Joseph K. Han, MD
Professor, EVMS
Chief, Division of Rhinology and Endoscopic Sinus-Skull Base Surgery
Chief, Division of Allergy
President Elect, ARS
Chair Elect, AAAAI, RROAC
Eastern Virginia Medical School
Norfolk, VA


Anju T. Peters, MD, MS
Professor, Medicine
Division of Allergy-Immunology
Director, Clinical Research
Northwestern University Feinberg School of Medicine
Chicago, IL


Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Peter Lio, MD, FAAD
Consultant/Independent Contractor: AbbVie, Amyris, AOBiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Grant/Research Support: AbbVie, National Eczema Association, Regeneron/Sanofi Genzyme.
Honoraria: AbbVie, Amyris, AObiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Speaker’s Bureau: Galderma, L’Oréal, Pfizer, Regeneron/Sanofi Genzyme.
Advisory Board: AbbVie, Amyris, AOBiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Stock Shareholder: Altus Labs, Micreos, YoBee.
Other Royalty: Theraplex AIM (OTC product) Royalties. 

Joseph K. Han, MD
Consultant/Independent Contractor: AstraZeneca, Genentech, GlaxoSmithKline, Novartis, Sanofi Regeneron.

Anju T. Peters, MD, MS
Grant/Research Support: AstraZeneca, Optinose (Research Support is to Institution)
Advisory Board: AstraZeneca, GlaxoSmithKline, Optinose, Sanofi Regeneron.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Lindsay Borvansky has nothing to disclose.
Andrea Funk has nothing to disclose.
Liddy Knight has nothing to disclose.
Ashley Cann has nothing to disclose.
Deborah Liao has nothing to disclose.
Sharon Powell has nothing to disclose.
Elizabeth Johnson has nothing to disclose. 

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and RMEI Medical Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians. 

Physician Credit Designation

Global Education Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

There is no fee for this educational activity. 

This activity was released on December 21, 2020 and is valid for one year. Requests for credit must be made no later than December 20, 2021.

In order to receive credit for this activity, the participant must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity post-test (score 75% or higher) and evaluation.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals. 

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and RMEI Medical Education, LLC do not recommend the use of any agent outside of the labeled indications.   

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Contact Information for Questions About the Activity

For information about the accreditation of this program, please contact Global Education Group at 303-395-1782 or cme@globaleducationgroup.com. 

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)™/
MOC Point(s)
Released: December 21, 2020
Expires: December 20, 2021
15 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and RMEI Medical Education, LLC.

Target Audience

The educational design of this activity addresses the needs of physicians who specialize in allergy/immunology, dermatology, otolaryngology, pulmonology, and primary care.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Recognize adverse events related to biologics used to treat atopic diseases
  • Describe how to work with a multidisciplinary team to develop a treatment strategy for patients with multiple coexisting atopic diseases

Activity Description

In this interactive panel discussion, 3 multidisciplinary clinical opinion leaders discuss management solutions for a real-world atopic dermatitis patient case that was selected from a community-based clinician submission.

Statement of Educational Need

Advances in understanding the pathophysiology of atopic diseases highlight the importance and commonality of underlying type 2 inflammation in a range of diseases like asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps. Key drivers of type 2 inflammation have been identified, with IL-4 and IL-13 playing a central role. In the last few years, biologics targeting type 2 inflammation have emerged as effective treatment options for patients with atopic diseases, particularly in people with moderate-to-severe disease. Because of the relative novelty of these treatments, healthcare professionals should be aware of the pathophysiology of disease, as well as the efficacy, safety, and tolerability of biologics, the rationale for use, and how to incorporate these treatments into management of appropriate patients. 

Faculty

Peter A. Lio, MD, FAAD
Clinical Assistant Professor, Dermatology & Pediatrics
Northwestern University Feinberg School of Medicine
Chicago, IL


Joseph K. Han, MD
Professor, EVMS
Chief, Division of Rhinology and Endoscopic Sinus-Skull Base Surgery
Chief, Division of Allergy
President Elect, ARS
Chair Elect, AAAAI, RROAC
Eastern Virginia Medical School
Norfolk, VA


Anju T. Peters, MD, MS
Professor, Medicine
Division of Allergy-Immunology
Director, Clinical Research
Northwestern University Feinberg School of Medicine
Chicago, IL


Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Peter Lio, MD, FAAD
Consultant/Independent Contractor: AbbVie, Amyris, AOBiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Grant/Research Support: AbbVie, National Eczema Association, Regeneron/Sanofi Genzyme.
Honoraria: AbbVie, Amyris, AObiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Speaker’s Bureau: Galderma, L’Oréal, Pfizer, Regeneron/Sanofi Genzyme.
Advisory Board: AbbVie, Amyris, AOBiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Stock Shareholder: Altus Labs, Micreos, YoBee.
Other Royalty: Theraplex AIM (OTC product) Royalties. 

Joseph K. Han, MD
Consultant/Independent Contractor: AstraZeneca, Genentech, GlaxoSmithKline, Novartis, Sanofi Regeneron.

Anju T. Peters, MD, MS
Grant/Research Support: AstraZeneca, Optinose (Research Support is to Institution)
Advisory Board: AstraZeneca, GlaxoSmithKline, Optinose, Sanofi Regeneron.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Lindsay Borvansky has nothing to disclose.
Andrea Funk has nothing to disclose.
Liddy Knight has nothing to disclose.
Ashley Cann has nothing to disclose.
Deborah Liao has nothing to disclose.
Sharon Powell has nothing to disclose.
Elizabeth Johnson has nothing to disclose. 

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and RMEI Medical Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians. 

Physician Credit Designation

Global Education Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

There is no fee for this educational activity. 

This activity was released on December 21, 2020 and is valid for one year. Requests for credit must be made no later than December 20, 2021.

In order to receive credit for this activity, the participant must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity post-test (score 75% or higher) and evaluation.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals. 

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and RMEI Medical Education, LLC do not recommend the use of any agent outside of the labeled indications.   

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Contact Information for Questions About the Activity

For information about the accreditation of this program, please contact Global Education Group at 303-395-1782 or cme@globaleducationgroup.com. 

0.50 CME
Global Education Group
Trending Clinical Issues Influencing HIV Practice Today: An Online and Mobile Mini-Curriculum—A Practical Approach to Addressing Mental Health in HIV

Trending Clinical Issues Influencing HIV Practice Today: An Online and Mobile Mini-Curriculum—A Practical Approach to Addressing Mental Health in HIV

Start

Trending Clinical Issues Influencing HIV Practice Today: An Online and Mobile Mini-Curriculum—A Practical Approach to Addressing Mental Health in HIV

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: November 12, 2020
Expires: November 12, 2021
30 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and Integritas Communications.

Target Audience

The educational design of this activity addresses the needs of physicians, physician assistants, and nurse practitioners involved in the treatment of patients with human immunodeficiency virus (HIV).

Learning Objectives

After completing this activity, the participant should be better able to:

  • Implement screening and appropriate treatment strategies for depression in patients with HIV to optimize adherence and retention in care

Activity Description

This multi-media activity, comprised of slides and graphics with expert audio commentary, is 1 in a series of 4 online, mobile mini-curricula that have been designed to address identified knowledge and practice gaps among infectious disease and HIV specialists, with the overall goal of the program to improve the care of patients with HIV.

Statement of Educational Need

Depression is common in patients with HIV and can result in nonadherence and reduced levels of viral suppression.1,2 Clinicians should be aware of the relationship between stigma, social isolation, and depression, which may be particularly severe in people of color and men who have sex with men (MSM).3 Pharmacologic treatment of depression can greatly improve quality of life, adherence, and, therefore, viral suppression. Depression is not the only factor that may affect a patient’s mental health. Substance use disorder, or even recreational substance use, which is not uncommon in the HIV population, like depression, may result in reduced adherence or viral suppression.4,5 Patients should be screened in a nonjudgmental manner so that they may be referred to addiction programs or mental health professionals.6 Through a peer-to-peer discussion, Dr. Elion and Dr. Treisman provide straightforward strategies that an HIV specialist can use to screen for and address both mental health disorders and substance use in patients with HIV.
 

  1. Gokhale RH, Weiser J, Sullivan PS, Luo Q, Shu F, Bradley H. Depression prevalence, antidepressant treatment status and association with sustained HIV in care in the United States, 2009-2014. AIDS Behav. 2019;23(12):3452-3459.
  2. Mills JC, Harman JS, Cook RL, et al. Comparative effectiveness of dual vs. single-action antidepressants on HIV clinical outcomes in HIV-infected people with depression.  AIDS. 2017;31(18):2515-2524.
  3. Rhodes SD, Hergenrather KC, Vissman AT, et al. Boys must be men, and men must have sex with men: a qualitative CBPR study to explore sexual risk among African American, Latino, and white gay men and MSM. Am J Mens Health. 2011;5(2):140-151.
  4. Bositis CM, St. Louis J. HIV and substance use disorder: role of the HIV physician. Infect Dis Clin North Am. 2019;33(3):835-855.
  5. Hartzler B, Dombrowski JC, Williams JR, et al. Influence of substance use disorders on 2-year HIV care retention in the United States. AIDS Behav. 2018;22(3):742-751.
  6. US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. 2019; https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv/whats-new-guidelines. Accessed September 14, 2020.

Faculty

Richard Elion, MD
Clinical Professor of Medicine
George Washington University, School of Medicine
Washington, District of Columbia

Glenn Jordan Treisman, MD, PhD
Director, AIDS Psychiatry Service
Professor of Psychiatry and Behavioral Sciences
Johns Hopkins University School of Medicine
Baltimore, Maryland

Disclosure of Conflicts of Interest

Global requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Richard Elion, MD: Consultant/Independent Contractor, Speakers Bureau: Gilead Sciences, Inc.; Grant/Research Support, Honoraria: Gilead Sciences, Inc., ViiV Healthcare Limited; Other: Work with Trio Health, who gets grants from Gilead Sciences, Inc. and ViiV Healthcare Limited

Glenn Jordan Treisman, MD, PhD: Nothing to disclose

The following planners and managers reported no financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Lindsay Borvansky, Andrea Funk, Liddy Knight, Ashley Cann, Gena Dolson, MS, Stacey JP Ullman, MHS, Jim Kappler, PhD

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must score 75% on the posttest and complete the program evaluation.

Statement of Commercial Support

This activity is supported by an educational grant from Gilead Sciences, Inc.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global and Integritas Communications do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Global Contact Information

For information about the accreditation of this program, please contact Global Education Group at 303-395-1782 or cme@globaleducationgroup.com.

Trending Clinical Issues Influencing HIV Practice Today: An Online and Mobile Mini-Curriculum—A Practical Approach to Addressing Mental Health in HIV

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: November 12, 2020
Expires: November 12, 2021
30 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and Integritas Communications.

Target Audience

The educational design of this activity addresses the needs of physicians, physician assistants, and nurse practitioners involved in the treatment of patients with human immunodeficiency virus (HIV).

Learning Objectives

After completing this activity, the participant should be better able to:

  • Implement screening and appropriate treatment strategies for depression in patients with HIV to optimize adherence and retention in care

Activity Description

This multi-media activity, comprised of slides and graphics with expert audio commentary, is 1 in a series of 4 online, mobile mini-curricula that have been designed to address identified knowledge and practice gaps among infectious disease and HIV specialists, with the overall goal of the program to improve the care of patients with HIV.

Statement of Educational Need

Depression is common in patients with HIV and can result in nonadherence and reduced levels of viral suppression.1,2 Clinicians should be aware of the relationship between stigma, social isolation, and depression, which may be particularly severe in people of color and men who have sex with men (MSM).3 Pharmacologic treatment of depression can greatly improve quality of life, adherence, and, therefore, viral suppression. Depression is not the only factor that may affect a patient’s mental health. Substance use disorder, or even recreational substance use, which is not uncommon in the HIV population, like depression, may result in reduced adherence or viral suppression.4,5 Patients should be screened in a nonjudgmental manner so that they may be referred to addiction programs or mental health professionals.6 Through a peer-to-peer discussion, Dr. Elion and Dr. Treisman provide straightforward strategies that an HIV specialist can use to screen for and address both mental health disorders and substance use in patients with HIV.
 

  1. Gokhale RH, Weiser J, Sullivan PS, Luo Q, Shu F, Bradley H. Depression prevalence, antidepressant treatment status and association with sustained HIV in care in the United States, 2009-2014. AIDS Behav. 2019;23(12):3452-3459.
  2. Mills JC, Harman JS, Cook RL, et al. Comparative effectiveness of dual vs. single-action antidepressants on HIV clinical outcomes in HIV-infected people with depression.  AIDS. 2017;31(18):2515-2524.
  3. Rhodes SD, Hergenrather KC, Vissman AT, et al. Boys must be men, and men must have sex with men: a qualitative CBPR study to explore sexual risk among African American, Latino, and white gay men and MSM. Am J Mens Health. 2011;5(2):140-151.
  4. Bositis CM, St. Louis J. HIV and substance use disorder: role of the HIV physician. Infect Dis Clin North Am. 2019;33(3):835-855.
  5. Hartzler B, Dombrowski JC, Williams JR, et al. Influence of substance use disorders on 2-year HIV care retention in the United States. AIDS Behav. 2018;22(3):742-751.
  6. US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. 2019; https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv/whats-new-guidelines. Accessed September 14, 2020.

Faculty

Richard Elion, MD
Clinical Professor of Medicine
George Washington University, School of Medicine
Washington, District of Columbia

Glenn Jordan Treisman, MD, PhD
Director, AIDS Psychiatry Service
Professor of Psychiatry and Behavioral Sciences
Johns Hopkins University School of Medicine
Baltimore, Maryland

Disclosure of Conflicts of Interest

Global requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Richard Elion, MD: Consultant/Independent Contractor, Speakers Bureau: Gilead Sciences, Inc.; Grant/Research Support, Honoraria: Gilead Sciences, Inc., ViiV Healthcare Limited; Other: Work with Trio Health, who gets grants from Gilead Sciences, Inc. and ViiV Healthcare Limited

Glenn Jordan Treisman, MD, PhD: Nothing to disclose

The following planners and managers reported no financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Lindsay Borvansky, Andrea Funk, Liddy Knight, Ashley Cann, Gena Dolson, MS, Stacey JP Ullman, MHS, Jim Kappler, PhD

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must score 75% on the posttest and complete the program evaluation.

Statement of Commercial Support

This activity is supported by an educational grant from Gilead Sciences, Inc.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global and Integritas Communications do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Global Contact Information

For information about the accreditation of this program, please contact Global Education Group at 303-395-1782 or cme@globaleducationgroup.com.

1.25 CME
Vindico
Systemic Lupus Erythematosus Management in a New Decade: Treat to Target, But Don’t Stop There

Systemic Lupus Erythematosus Management in a New Decade: Treat to Target, But Don’t Stop There

Start

Systemic Lupus Erythematosus Management in a New Decade: Treat to Target, But Don’t Stop There

Activity Details

Free CME
1.25 AMA PRA Category 1 Credit(s)
Released: December 8, 2020
Expires: December 7, 2021
75 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is rheumatologists and other health care professionals involved in the management of patients with systemic lupus erythematosus.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Review the immunopathology underlying systemic lupus erythematosus (SLE) and the implications for disease manifestations, burden, and treatment.
  • Assess patients with SLE for visceral organ involvement as well as steroid toxicity and manage accordingly.
  • Assess patients being treated for SLE for disease activity to ensure treatment to desired clinical target and symptom control.
  • Select treatment for children or adults with SLE based on the latest clinical evidence and guidelines.
  • Review the importance of effective communication, counseling, and shared decision-making strategies to improve adherence and satisfaction with care for patients with SLE.

Activity Description

Systemic lupus erythematosus (SLE) is an autoimmune disease that affects both children and adults, with women of childbearing age being at greatest risk. Individuals diagnosed with SLE can have widespread inflammation and tissue damage affecting multiple organ systems, including the skin, joints, kidneys, and the brain. Ongoing education is essential for providing evidence-based care for this complex disease. In this educational program featuring clinical case examples, experts will provide an overview of SLE immunopathology and offer guidance on assessment of disease activity, visceral organ involvement, and steroid toxicity. Faculty will review optimal management approaches per treatment guidelines, present recent clinical data, and highlight therapeutic advancements. Strategies for utilizing effective communication and shared decision-making to improve therapy adherence and patient satisfaction will be discussed.

Agenda

Introduction: Lupus—A Historical Perspective
Leonard H. Calabrese, DO

Immunopathogenesis of SLE: Implications for Disease Manifestations and Treatment
Daniel J. Wallace, MD, FACP, MACR

Advances in the Treatment of SLE
Richard A. Furie, MD
 
Clinical Cases
Moderated by Leonard H. Calabrese, DO

Activity Chair

Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH

Disclosures:
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Crescendo, Genentech, Gilead, GlaxoSmithKline, Horizon, Janssen, Kiniksa, Lilly, Pfizer, Sanofi-Regeneron, UCB
Speakers Bureau: AbbVie, Bristol-Myers Squibb, Crescendo, Genentech, Horizon, Sanofi, UCB

Faculty

Richard A. Furie, MD
Professor of Medicine
Zucker School of Medicine at Hofstra/Northwell
Chief, Division of Rheumatology
Northwell Health
Great Neck, NY

Disclosures:
Consulting Fee: AstraZeneca, Aurinia, Genentech, GlaxoSmithKline

Daniel J. Wallace, MD, FACP, MACR
Associate Director, Rheumatology Fellowship Program
Board of Governors, Cedars-Sinai Medical Center
Professor of Medicine, Cedars-Sinai Medical Center
David Geffen School of Medicine Center at UCLA
Los Angeles, CA

Disclosures:
Consulting Fee: Aurinia, EMD Serono, GlaxoSmithKline, Lilly, Pfizer

Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, faculty, and reviewers involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, December 8, 2020 to December 7, 2021.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 4 of the 5 posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This educational activity is supported by an educational grant from GlaxoSmithKline.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Systemic Lupus Erythematosus Management in a New Decade: Treat to Target, But Don’t Stop There

Activity Details

Free CME
1.25 AMA PRA Category 1 Credit(s)
Released: December 8, 2020
Expires: December 7, 2021
75 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is rheumatologists and other health care professionals involved in the management of patients with systemic lupus erythematosus.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Review the immunopathology underlying systemic lupus erythematosus (SLE) and the implications for disease manifestations, burden, and treatment.
  • Assess patients with SLE for visceral organ involvement as well as steroid toxicity and manage accordingly.
  • Assess patients being treated for SLE for disease activity to ensure treatment to desired clinical target and symptom control.
  • Select treatment for children or adults with SLE based on the latest clinical evidence and guidelines.
  • Review the importance of effective communication, counseling, and shared decision-making strategies to improve adherence and satisfaction with care for patients with SLE.

Activity Description

Systemic lupus erythematosus (SLE) is an autoimmune disease that affects both children and adults, with women of childbearing age being at greatest risk. Individuals diagnosed with SLE can have widespread inflammation and tissue damage affecting multiple organ systems, including the skin, joints, kidneys, and the brain. Ongoing education is essential for providing evidence-based care for this complex disease. In this educational program featuring clinical case examples, experts will provide an overview of SLE immunopathology and offer guidance on assessment of disease activity, visceral organ involvement, and steroid toxicity. Faculty will review optimal management approaches per treatment guidelines, present recent clinical data, and highlight therapeutic advancements. Strategies for utilizing effective communication and shared decision-making to improve therapy adherence and patient satisfaction will be discussed.

Agenda

Introduction: Lupus—A Historical Perspective
Leonard H. Calabrese, DO

Immunopathogenesis of SLE: Implications for Disease Manifestations and Treatment
Daniel J. Wallace, MD, FACP, MACR

Advances in the Treatment of SLE
Richard A. Furie, MD
 
Clinical Cases
Moderated by Leonard H. Calabrese, DO

Activity Chair

Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH

Disclosures:
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Crescendo, Genentech, Gilead, GlaxoSmithKline, Horizon, Janssen, Kiniksa, Lilly, Pfizer, Sanofi-Regeneron, UCB
Speakers Bureau: AbbVie, Bristol-Myers Squibb, Crescendo, Genentech, Horizon, Sanofi, UCB

Faculty

Richard A. Furie, MD
Professor of Medicine
Zucker School of Medicine at Hofstra/Northwell
Chief, Division of Rheumatology
Northwell Health
Great Neck, NY

Disclosures:
Consulting Fee: AstraZeneca, Aurinia, Genentech, GlaxoSmithKline

Daniel J. Wallace, MD, FACP, MACR
Associate Director, Rheumatology Fellowship Program
Board of Governors, Cedars-Sinai Medical Center
Professor of Medicine, Cedars-Sinai Medical Center
David Geffen School of Medicine Center at UCLA
Los Angeles, CA

Disclosures:
Consulting Fee: Aurinia, EMD Serono, GlaxoSmithKline, Lilly, Pfizer

Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, faculty, and reviewers involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, December 8, 2020 to December 7, 2021.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 4 of the 5 posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This educational activity is supported by an educational grant from GlaxoSmithKline.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Pages